Case Studies in Thyroid Cancer

Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.

Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.

Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.

The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.

Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.

Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.

Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.

Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.

Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.

Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.

Marcia Brose, MD, discusses the efficacy and safety data of a phase 2 trial examining lenvatinib dose reductions in patients with RAI-DTC.

Lori Wirth, MD, presents the case of a 60-year-old man with RET+ metastatic medullary thyroid cancer.

Lori Wirth, MD, and Andrew Gianoukakis, MD, discuss patient and clinical characteristics necessitating thyroidectomy in patients with thyroid cancer.

Dr Wirth reviews disease management considerations a 60-year-old man with RET+ metastatic medullary thyroid cancer.

The panel of experts discuss the importance of molecular testing and RET mutations in thyroid cancer disease management.

Experts in the management of thyroid cancer share their treatment recommendations for a 60-year-old man with RET+ metastatic medullary thyroid cancer.

Lori Wirth, MD, discusses the mechanism of action of selpercatinib and key data from the LIBRETTO-001 and LIBRETTO-531 clinical trials.

The panel of experts discuss practical considerations regarding selpercatinib and the LIBRETTO-001 and LIBRETTO-531 clinical trial data.

Lori Wirth, MD, discusses the mechanism of action of pralsetinib and key data from the phase 1/2 ARROW clinical trial.

Marcia Brose, MD, presents the case of a 64-year-old woman with RET wild-type metastatic medullary thyroid cancer.

Dr Marcia Brose reviews key efficacy and safety data from the phase 3 ZETA and EXAM clinical trials.

The panel of experts share their treatment recommendations for a 64-year-old woman with RET wild-type metastatic MTC.